Difference between revisions of "Team:NCTU Formosa/Composite Part"

Line 259: Line 259:
 
</div>
 
</div>
 
<div class="goto1">
 
<div class="goto1">
−
<a href="https://2015.igem.org/Team:NCTU_Formosa/LabSafety"><img src="https://static.igem.org/mediawiki/2015/c/c2/%E7%AE%AD%E9%A0%AD2.png"; width=50vw;><br><br>Go to Lab Safety</a>
+
<a href="https://2015.igem.org/Team:NCTU_Formosa/Practices"><img src="https://static.igem.org/mediawiki/2015/c/c2/%E7%AE%AD%E9%A0%AD2.png"; width=50vw;><br><br>Go to Practices</a>
 
</div>
 
</div>
 
</div>
 
</div>

Revision as of 09:17, 18 September 2015

Composite Parts

Composite Part

BBa_K1694013
OmpA-anti-VEGF
BBa_K1694014
OmpA-anti-EGFR
BBa_K1694015
OmpA-anti-HER2
In order to change the scFv parts easily, we added a NcoI restriction site between OmpA and scFv so that we can change various scFv DNA sequence using the NcoI restriction enzyme.
BBa_K1694023
Pcons+RBS+OmpA-anti-VEGF
BBa_K1694024
Pcons+RBS+OmpA-anti-EGFR
BBa_K1694025
Pcons+RBS+OmpA-anti-HER2
By ligating the constitutive promoter (BBa_J23101), strong ribosome binding site (BBa_B0034) and Lpp-OmpA-scFv, we were able to display scFv on the E. coli outer membrane continuously. Having this part, we can co-transform with other parts in order to produce color as the detection signal.

In addition, by co-transforming these different types of E. coli with different fluorescence or color as signals, we are able to create a platform which can detect multimarker and consequently achieve combination therapy.
BBa_K1694033
Pcons+RBS+OmpA-anti-VEGF+RBS+GFP+Ter
BBa_K1694034
Pcons+RBS+OmpA-anti-EGFR+RBS+GFP+Ter
BBa_K1694035
Pcons+RBS+OmpA-anti-HER2+RBS+GFP+Ter
BBa_K1694044
Pcons+RBS+OmpA-anti-EGFR+RBS+RFP+Ter
BBa_K1694045
Pcons+RBS+OmpA-anti-HER2+RBS+BFP+Ter
The most commonly constructing way of composite parts is to ligate the required parts together. We also provide this kind of parts.
At the back of the Lpp-OmpA-scFv part, we ligated the weaker ribosome biding site (BBa_B0030), different fluorescent protein and terminator (BBa_J61048) to make it continuously and simultaneously express the fluorescence and the scFv. We used a weak ribosome binding site to ensure that scFv's production will not be affected.
BBa_K1694053
Pcons+RBS+OmpA-anti-VEGF+RBS+amilCP+Ter
BBa_K1694054
Pcons+RBS+OmpA-anti-EGFR+RBS+amilCP+Ter
BBa_K1694055
Pcons+RBS+OmpA-anti-HER2+RBS+amilCP+Ter
Chromoprotein is another example of what can be added when making your own probe.
We constructed this part as the Pcons+RBS+OmpA-scFv+RBS+fluorescent protein+Terminator part.
BBa_K1694027
Pinduce+RBS+FadL-GBP
By ligating the induced promoter (BBa_R0010), ribosome binding site (BBa_B0034) and FadL-GBP, we can continuously display the GBP on the E. coli outer membrane.
Then we co-transform the OmpA-scFv parts and this FadL-GBP parts into the same E. coli, hence allowing our E. coli to bind on gold chips and detect antigens simultaneously.
BBa_K1694037
Pinduce+RBS+FadL-GBP+RBS+GFP+Ter
With this part, we can test the GBP function by observing the green fluorescence on the gold chip. Terminator is (BBa_B0015),
Reference
 [1] C Hartmann et al. (2010) Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response
[2] DrugBank: Bevacizumab (DB00112)
[3] DrugBank: Cetuximab (DB00002)
[4] DrugBank: Trastuzumab (DB00072)
[5] Tae Jung Park et al. (2009) Development of a whole-cell biosensor by cell surface display of a gold-binding polypeptide on the gold surface


Back to project


Go to Practices
<groupparts>iGEM15 NCTU_Formosa</groupparts>